In vitro and in vivo evaluation of hydrophilic and hydrophobic polymers-based nicorandil-loaded peroral tablet compared with its once-daily commercial sustained-release tablet
- 6 September 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Drug Development and Industrial Pharmacy
- Vol. 37 (4), 436-445
- https://doi.org/10.3109/03639045.2010.521161
Abstract
Context: Hydrophilic and hydrophobic polymer-based nicorandil (10 mg)-loaded peroral tablets were prepared using the wet granulation technique. The influence of varying amounts of hydroxypropyl methylcellulose (HPMC) (30–50 mg), ethylcellulose (2–4 mg), microcrystalline cellulose (5–20 mg) and Aerosil® (5–12 mg) in conjunction with the constant amounts (3 mg) of glidant and lubricant (magnesium stearate and talc) on the in vitro performances of the tablets (hardness, friability, weight variation, thickness uniformity, drug content, and drug release behavior) were investigated. Objective: The objectives of this study were (i) to select a nicorandil-loaded peroral tablet that matched the in vitro dissolution profile of once-daily commercial sustained-release tablet, and (ii) to compare the in vivo sustaining/controlling efficacy of the selected peroral tablet with that of its commercial counterparts. Results and Discussion: Because the nicorandil (10 mg)-loaded tablet prepared based on F-IX composition (50 mg HPMC, 4 mg ethylcellulose, 10 mg MCC and 3 mg glidant and lubricant) showed a release profile comparable to that of the Nikoran® OD SR tablet release profile, the tablet with this composition was considered to be the optimized/selected formulation and, therefore, was subjected to stability study and in vivo study in rabbits. Despite of the higher Cmax and AUC values obtained with the optimized tablet, there was no sign of difference between the optimized- and Nikoran® OD SR- tablets following a single-dose crossover oral administration into rabbit. Conclusion: The optimized tablet could be used as an alternative to the commercial once-daily tablet.Keywords
This publication has 11 references indexed in Scilit:
- Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymerEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Quantitation of nicorandil in pharmaceutical formulations by spectrophotometry using N-(1-naphthyl) ethylenediamine dihydrochloride as coupling agent.YAKUGAKU ZASSHI, 2007
- Once-daily sustained-release matrix tablets of nicorandil: Formulation and in vitro evaluationAAPS PharmSciTech, 2003
- Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trialThe Lancet, 2002
- Determination of nicorandil concentrations in human plasma using liquid chromatographyJournal of Pharmaceutical and Biomedical Analysis, 1999
- Development and Evaluation of Controlled-Release Diltiazem HCl Microparticles Using Cross-Linked Poly(Vinyl Alcohol)Drug Development and Industrial Pharmacy, 1997
- NicorandilDrugs, 1992
- Clinical Pharmacology of Potassium Channel OpenersBasic & Clinical Pharmacology & Toxicology, 1992
- Pharmacology and therapeutic effects of nicorandilCardiovascular Drugs and Therapy, 1990
- Hydroxypropylmethylcellulose sustained release technologyDrug Development and Industrial Pharmacy, 1989